Subject Evaluation of a 1064nm Diode Laser/RF

NCT04090853 | Withdrawn FDA Device

• 1 other identifier: BL1119
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 3

Brief Summary

Open-label, baseline-controlled, multi-center study evaluating a 1064 nm diode laser, pulsed electromagnetic fields and vacuum assisted radio frequency for non-invasive fat reduction of the abdomen and flanks.

Conditions

Subcutaneous Fat Disorder

Outcome Measures

Primary Outcomes (2)

• Patient Overall Satisfaction

  Patients rate their satisfaction with treatment outcomes at the final follow up visit using a patient survey by answering 12 questions

  Week 26

• Patient Treatment Satisfaction

  Patients rate their treatment satisfaction using a 5 point Likert Scale. The Likert scale ranges from 1 = very unsatisfied 2 = unsatisfied 3 = neutral 4 = satisfied 5 = very satisfied

  Week 26

Study Arms (1)

Patient Treatment Group

OTHER

Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.

Device: Venus Bliss

Interventions

Venus Bliss DEVICE

The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.

Patient Treatment Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to read, understand and voluntarily provide written informed consent.
• Healthy male or female, ≥ 18 years of age seeking treatment for unwanted fat in the flanks and or abdomen
• BMI score is less than 35.
• Able and willing to comply with the treatment/follow-up schedule and requirements.
• Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline.

You may not qualify if:

• Pregnant, intending to become pregnant, postpartum or nursing in the last 6 months.
• Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
• History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications, 6 months prior to and during the course of the study.
• History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
• Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants, thrombolytics or anti-inflammatory medications within 2 weeks of treatment.
• Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
• Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone or parenteral gold therapy (gold sodium thiomalate).
• Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelength used or history of photosensitivity disorder.
• Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
• Tattoos in the treatment area.
• Poor skin quality (severe laxity).
• Abdominal wall, muscular abnormality or hernia on physical examination.
• Use of retinoids such as oral isotretinoin (Accutane™) within the past six months or during course of the study.
• History of keloid or hypertrophic scar formation or poor wound healing in the treatment area.
• As per the investigator's discretion, any physical or mental condition which may make it unsafe for the subject to participate.

Sponsors & Collaborators

• Venus Concept: lead

Study Sites (3)

Shah Aesthetic Surgery

Denver, Colorado, 80206, United States

Location

Medical Management Solutions INC

Foxborough, Massachusetts, 02035, United States

Location

SRS Dermatology

Woodmere, New York, 11598, United States

Location

Study Officials

• Yoni Iger

  Venus Concept LTD

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single group assessed patient feedback regarding satisfaction post treatment

Study Record Dates

• First Submitted: September 12, 2019
• First Posted: September 16, 2019
• Study Start: October 1, 2019
• Primary Completion: July 8, 2020
• Study Completion: July 8, 2020
• Last Updated: May 8, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)